Tax withholding trims Aurinia (AUPH) CFO stake by 32,424 shares

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller reported a tax-related share disposition. On the vesting of restricted stock units, 32,424 shares of common stock were withheld at $14.40 per share to cover tax obligations, according to the footnote. After this withholding transaction, Miller directly owned 556,703 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Joseph M

(Last) (First) (Middle)

#140, 14315 -118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		F		32,424(1)	D	$14.4	556,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Remarks:

	/s/ Joseph M. Miller	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aurinia Pharmaceuticals (AUPH) report for its CFO?

Aurinia’s Chief Financial Officer Joseph M. Miller reported a tax-withholding disposition of 32,424 common shares. The shares were withheld upon vesting of restricted stock units to satisfy tax obligations, rather than sold on the open market.

Was the Aurinia (AUPH) CFO’s Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. The Form 4 describes a tax-withholding disposition, where 32,424 vested shares were withheld by the company to cover tax liabilities tied to restricted stock unit vesting.

How many Aurinia (AUPH) shares were involved in the CFO’s tax-withholding?

The Form 4 shows 32,424 shares of Aurinia common stock were withheld. These shares were used to satisfy tax withholding obligations triggered by the vesting of restricted stock units held by Chief Financial Officer Joseph M. Miller.

What price per share was used in the Aurinia (AUPH) CFO withholding transaction?

The reported tax-withholding disposition used a price of $14.40 per share. This price applies to the 32,424 shares of common stock withheld to cover the CFO’s tax liabilities from restricted stock unit vesting.

How many Aurinia (AUPH) shares does the CFO own after this Form 4 transaction?

Following the tax-withholding disposition, Chief Financial Officer Joseph M. Miller directly owned 556,703 Aurinia common shares. This figure reflects his direct holdings after 32,424 shares were withheld to satisfy associated tax obligations.

What does transaction code "F" mean in the Aurinia (AUPH) Form 4 filing?

Transaction code “F” indicates a tax-withholding disposition. In this case, 32,424 vested shares of Aurinia common stock were withheld to pay exercise price or tax liabilities, rather than being bought or sold on the open market.